Business Context and Reporting Period
Company: PharmAthene, Inc. (Note: Metadata referenced Altimmune, Inc., but the filing text identifies the registrant as PharmAthene, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: PharmAthene is a biopharmaceutical company focused on developing biodefense countermeasures against biological and chemical weapons. The company operates in a single segment and relies heavily on U.S. government contracts (DoD, NIAID, BARDA) for revenue. Key product candidates include SparVax (anthrax vaccine), Valortim (anthrax antibody), Protexia (nerve agent protectant), and RypVax (plague vaccine).
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenue | $5.52 million | $5.84 million |
| Net Loss | $(6.01) million | $(4.75) million |
| Loss Per Share (Basic/Diluted) | $(0.23) | $(0.22) |
| Operating Cash Flow | $(6.77) million | $(5.27) million |
| Cash and Cash Equivalents (End of Period) | $17.25 million | $19.24 million |
| Short-Term Investments | $6.77 million | $3.19 million |
| Total Debt (Current + Long-Term) | $17.78 million | $18.31 million |
| Accumulated Deficit | $(129.83) million | $(123.82) million |
Note: Total Debt includes $13.83 million in Convertible Notes and $3.95 million in current portion of long-term debt. Long-term debt was $0 at March 31, 2009.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately $0.32 million (5.5%) compared to Q1 2008. This was primarily driven by a $3.2 million decrease in Protexia revenue as the program shifted from development to Phase I clinical trials, partially offset by new revenue from the Avecia Acquisition (SparVax and RypVax).
- Increased Net Loss: Net loss widened by $1.26 million to $6.01 million. This increase was driven by higher General and Administrative (G&A) expenses ($0.79 million increase) due to compliance, legal, and litigation costs, and increased share-based compensation ($0.40 million increase).
- Operating Expenses: Total operating expenses rose to $11.03 million from $10.48 million. R&D expenses decreased slightly ($0.23 million) due to reduced process development for Protexia, but G&A expenses increased significantly.
- Accounting Changes: Adoption of EITF 07-5 resulted in the reclassification of certain warrants from equity to liability, impacting the balance sheet and introducing mark-to-market volatility in other income/expense.
Guidance, Outlook, and Risks
- Liquidity and Capital Needs: Management states that at the current rate of cash consumption, the company will need to obtain additional financing no later than the first quarter of 2010. The company has not generated positive cash flow since inception.
- Recent Financing: On March 27, 2009, the company completed a public offering of 2.1 million shares and warrants, raising gross proceeds of $5.5 million (net proceeds approx. $5.0 million).
- Contractual Obligations: The company has a $7.0 million letter of credit obligation related to the Avecia Acquisition, due by October 2, 2009, or upon a financing transaction of $15 million or more. Additionally, $10 million in milestone payments to Avecia are contingent on receiving a DHHS award for SparVax.
- Key Risks:
- Government Dependence: Substantially all revenue is derived from U.S. government contracts. Delays or cancellations in funding (e.g., the delayed RFP-BARDA-08-15 award for SparVax) pose a severe threat to operations.
- Going Concern: The company faces significant uncertainty regarding its ability to continue as a going concern without additional funding or contract awards.
- Manufacturing Transfer: The company is transitioning SparVax manufacturing from the UK to a U.S.-based facility, which carries risks of delays and technical failure.
Investor Verification Checklist
- Financing Timeline: Verify the company's ability to secure the necessary capital by Q1 2010 to avoid insolvency.
- RFP-BARDA-08-15 Status: Monitor the status of the Strategic National Stockpile anthrax vaccine award, which is critical for SparVax commercialization and triggering milestone payments.
- Debt Covenants: Review the terms of the $10 million credit facility and the $13.8 million convertible notes (maturing August 2009) for potential refinancing needs.
- Manufacturing Capability: Assess the progress of the technology transfer for SparVax to the new U.S. contract manufacturer.
- Warrant Liability: Monitor the fair value adjustments of warrant liabilities classified under EITF 07-5, which can cause volatility in net income.